Cyclophosphamide, adriamycin, and cisdiamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer

Publisher Website
Google Scholar
Abstract
Sixteen patients with regionally advanced or disseminated nonsquamous cell (NSC) head and neck cancer received a monthly combination chemotherapy regimen of cyclophosphamide (C), Adriamycin (A), and cis-diamminedichloroplatinum (II) (P), or P, as a single agent administered by either bolus or 24-hour infusion technique. Fifteen patients had received extensive prior surgery and/or radiation therapy. Three patients had prior chemotherapy. A response rate of 50% was achieved (8/16); there were 2 complete regressions and 6 partial regressions. The estimated median time to progression (TTP) for the entire group of 16 patients was 6.0 months and the estimated median survival was 14.0 months. Seven of 8 responders have progressed, with a median TTP of 10.7 months. Virtually all patients experienced alopecia as well as nausea and vomiting, which was more pronounced with the bolus administration of P. Myelosuppression was tolerable; there was no clinically significant renal impairment. Cancer 52:2007-2010, 1983.